Craft
Replimune

Replimune

Patients Reached

150

FY, 2018

Market Capitalization

$1.3 B

2023-01-24

Replimune Summary

Company summary

Overview
Replimune is developing novel, proprietary oncolytic immunotherapies intended to improve both the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released.
Type
Public
Status
Active
Founded
2015
HQ
Woburn, MA, US | view all locations
Website
http://www.replimune.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key people

  • Robert Coffin

    Robert Coffin, Founder, President and Chief Research & Development Officer, Director

    • Philip Astley-Sparke

      Philip Astley-Sparke, Chief Executive Officer & Director

      • Jason Rhodes, Director

        • Sander Slootweg, Director

          Operating MetricsView all

          Patients Reached

          150

          FY, 2018

          LocationsView all

          3 locations detected

          • Woburn, MA HQ

            United States

            18 Commerce Way

          • Woburn, MA

            United States

            500 Unicorn Park Dr 3rd floor

          • Milton, England

            United Kingdom

            69-70 Park Dr

          Replimune Financials

          Summary financials

          Net income (Q2, 2023)
          ($43.1M)
          Cash (Q2, 2023)
          $88.9M
          EBIT (Q2, 2023)
          ($41.6M)
          Enterprise value
          $1.3B

          Footer menu